◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › EWTX

Edgewise Therapeutics, Inc. (EWTX) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-09

Edgewise Therapeutics, Inc. (EWTX) operates in the Biotechnology industry and is headquartered in Boulder, United States with about 154 employees. Its market capitalization is roughly $5 billion. In the fiscal year ended 2025-12-31, EWTX reported $0M in revenue and ($168M) in net income.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.

Interactive charts & full statements →

EWTX Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($191M)($159M)($114M)($72M)
Net Income($168M)($134M)($100M)($68M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EWTX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($54M)($56M)($47M)($43M)($46M)
Net Income($49M)($50M)($41M)($36M)($41M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EWTX Free Cash Flow History

EWTX Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$553M$487M$340M$367M
Total Liabilities$30M$28M$21M$20M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EWTX viewer.

Other Companies in Biotechnology

← EWBCAll stocksEXC →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.